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A B S T R A C T
Background: Takotsubo syndrome is a stress cardiomyopathy, characterized by reversible left ventricle
(LV) apical ballooning in the absence of signiﬁcant angiographic coronary artery stenosis. The frequent
association with emotional stress suggests in this disease an autonomic nervous system involvement.
We could think that a therapeutic treatment targeting heart sympathetic dysfunction could be of crucial
importance.
Methods: From January 2010 to June 2012, 886 patients were consecutively evaluated at Cardarelli
Hospital, Naples, Italy. Among these, 48 patients met takotsubo cardiomyopathy (TCM) criteria. Each
patient was assessed with history and physical examination, 12-lead electrocardiogram, serum troponin,
coronary arteriography, and left ventricular angiogram, perfusion myocardial scintigraphy with
technetium 99m, with echocardiography and 123I-metaiodobenzylguanidine (MIBG) myocardial
scintigraphy. At discharge, the surviving patients were randomly assigned to a-lipoic acid (ALA)
treatment (600 mg once daily) or placebo. Following discharge, after the initial TCM event, patients
returned to our outpatient clinic at Internal Medicine of the Second University Naples for the follow-up
evaluation quarterly until 12 months. Routine analysis, myocardial damage serum markers, oxidative
stress serum markers, pro-inﬂammatory cytokines, and sympathetic tone activity were evaluated in all
patients.
Results: ALA administration improved MIBG defect size at 12 months compared to placebo.
Conclusions: Adrenergic cardiac innervation dysfunction in TCM patients persists after previous
experience of transient stress-induced cardiac dysfunction. ALA treatment improves the adrenergic
cardiac innervation. This study evaluates whether sympatho-vagal alterations are TCM event-related.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Takotsubo syndrome is a stress cardiomyopathy (TCM),
reported as a reversible form of acute heart failure, triggered by
stressful events and associated with a distinctive left ventricular
(LV) contraction pattern [1]. TCM mimics acute coronary syndrome reserved.
Fig. 1. The study ﬂow chart. The study was conducted in a population of stress
cardiomyopathy affected patients by following times: enrollment (886 patients),
allocation (24 patients received a-lipoic acid, ALA, vs. 24 received placebo), follow-up
and ﬁnal analysis (22 ALA patients vs. 21 placebo patients). SC, stress cardiomyopathy.
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absence of signiﬁcant angiographic coronary artery stenosis
[1]. The left ventricle of TCM patients shows a particular shape
resembling the Japanese ceramic ﬁshing pot for trapping octopus,
namely ‘‘takotsubo’’ [2]. Although the cause of this condition is still
unresolved, in this disease the frequent emotional stress associa-
tion suggests an autonomic nervous system involvement [3]. The
excessive release of hormones, such as adrenaline, produced in
high-stress situations, in TCM may cause heart muscle damage
[4,5]. In fact, TCM events have been reported after accidental
overdose of adrenaline [4] or associated with adrenaline-produc-
ing tumors, such as pheochromocytoma [5]. Thus, the sympathetic
activity dysfunction appears to play a key role in the TCM
pathophysiology. In most cases, in TCM patients, 123I-metaiodo-
benzylguanidine (MIBG) myocardial scintigraphy showed altered
123I MIBG distribution in several heart segments [6]. In more
detail, the apical myocardium shows poor sympathetic innerva-
tions and reduction of MIBG tracer uptake. A possible explanation
could be that the intense adrenaline discharge, acting on heart
segments with different and abnormal innervation, produces a
transient heart failure characterized by a particular LV shape. This
distinctive ‘‘takotsubo’’ shape has a narrow upper portion and a
lower enlarged portion that contracts poorly. Although TCM
presentation has been described [7,8], there are still few data from
large and prospective patient cohort studies following the initial
TCM event. In the majority of cases, transient myocardial-stunning
LV-related dysfunction involves the LV apical segments and there
is a full recovery within a few weeks. With proper recognition and
management, nearly all patients survive an acute takotsubo
episode [8]. However, in approximately 5% of patients, a second
(or third) stress-induced event may occur. Data suggest that the
TCM recurrence rates in the ﬁrst few years are likely in the range of
2–10% [2,9,10]. Because catecholamines may play a central role in
TCM pathogenesis, we could speculate that recurrence rates
should be lower in those patients maintained on comprehensive
adrenergic blockade. However, recent data indicate that these
drugs administered in traditional dosages did not absolutely
prevent either the ﬁrst or recurrent TCM episodes. In other words,
20–30% of these events occurred while beta-blockers were
administered [11]. Despite appropriate aggressive treatment,
about 5% of patients experienced either cardiac arrest (and
survived) or died during hospitalization [8]. In light of these
ﬁndings, since recurrent TCM is not entirely benign, a pharmaco-
logical treatment targeting the heart sympathetic dysfunction
could be of crucial importance. To date, a-lipoic acid (ALA)
administration has been shown to completely prevent heteroge-
neous MIBG distribution, decreasing MIBG uptake, and increasing
norepinephrine content in diabetic cardiomyopathy [12]. However,
the possible ALA treatment effect on TCM has not been examined
to date. ALA treatment has been shown to restore sympatho-vagal
alterations in diabetic cardiomyopathy [12,13], improving the
adrenergic cardiac innervation. ALA treatment may affect the
sympathetic tone balance by different action mechanisms as
observed in stress-induced cardiomyopathy [12,13]. The sympa-
thetic tone regulation may represent the therapeutic effect. We
could speculate that, in TCM, ALA treatment may induce a similar
effect regulating the complex interactions between vagal and
adrenergic cardiac innervations. Because in TCM the sympathetic
denervation appears to play a central role in disease pathogenesis
[3–6], we may test in our study the ALA’s therapeutic effect on
sympathetic and vagal tone activity. On this basis, this study aimed
to evaluate, in TCM patients, whether adrenergic cardiac innerva-
tion dysfunction and sympatho-vagal alterations persist after
previous experience of transient stress-induced cardiac dysfunc-
tion. For these reasons in this study we investigated, in TCM
patients, the ALA therapeutic effect compared to placebo.Methods
Patients
From January 2010 to June 2012, 886 patients with suspected ST
segment elevation myocardial infarction (STEMI) were referred to
Cardarelli Hospital, Naples, Italy, for coronary angiography and
consecutively evaluated at the Cardiac Intensive Care Unit (CICU) of
Cardarelli Hospital (Fig. 1). Among these, 48 patients met the criteria
for TCM: (I) acute onset of a cardiovascular event, usually associated
with substernal chest pain, initially regarded as STEMI/evolving
coronary syndrome; (II) cardiac biomarker modiﬁcations (creatine
kinase-MB and troponin I); (III) systolic dysfunction, predominantly
characterized by akinesia/hypokinesia of the mid-to-distal portion of
the LV chamber, with hypercontractile basal LV; (VI) absence, by
angiography, of signiﬁcant atherosclerotic luminal narrowing in each
of the 3 epicardial coronary arteries (0 to <25%); and (V) absence of
pheochromocytoma, myocarditis, or hypertrophic cardiomyopathy
[1]. Exclusion criteria were previous myocardial infarction, concomi-
tant chronic diseases including diabetes mellitus, kidney, liver, and
cerebrovascular diseases [1]. Informed consent was obtained from
each patient and the study protocol conforms tothe ethical guidelines
of the 1975 Declaration of Helsinki as reﬂected in a priori approval
by the institution’s human research committee. The Cardarelli
Hospital Institutional Review Board approved the protocol and the
informed consent was obtained from participants to the study.
Randomized trial
This study was performed in a double-blind using placebo
manner. This study was performed in 48 patients with TCM. Each
patient was assessed with history and physical examination, 12-
lead electrocardiogram, serum troponin, coronary arteriography,
and LV angiogram (an average of 6 h after admission to the
hospital), perfusion myocardial scintigraphy with technetium 99m
(99mTc), with echocardiography and MIBG myocardial scintigra-
phy. All patients were admitted to the CICU after coronary
angiography. Currently recommended treatments for acute coro-
nary syndromes, with therapy directed at relieving myocardial
ischemia and preventing thrombotic complications, were provided
to all patients [14]. At discharge, surviving patients with established
TCM were managed and followed for 12 months after the event as
outpatients. At discharge, the surviving patients were randomly
assigned to ALA treatment (600 mg once daily) (ALA group) or
placebo (placebo group). With regard to the full medical therapy, the
use of concomitant treatments were uniform between the groups
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coronary syndrome in all patients [14]. Following discharge, patients
returned to our outpatient clinic at Internal Medicine of the Second
University Naples for the follow-up evaluation quarterly until
12 months after the initial event of TCM.
Coronary angiography
Coronary angiograms at baseline were performed in at least
2 orthogonal views after intracoronary nitroglycerin. The analysis
of all angiographic data was performed by operators who were
unaware of the study groups (Inﬁnix CS-I angiograph, Toshiba,
Tokyo, Japan).
Echocardiography
LV function was evaluated in all patients by two-dimensional
echocardiography at admission, 14 days, and 12 months after the
acute event. Echocardiography (Philips IE 33, Eindhoven, The
Netherlands) was performed by operators, who were unaware of
the study groups, according to the international guidelines [15]. To
assess left ventricle wall contractility, authors evaluated the
echocardiographic score, that is wall motion score index. As
suggested by echocardiographic guidelines [15], the left ventricle
is divided into 5 walls: anterior, antero-septal, infero-septal,
postero-lateral, and antero-lateral. Each wall is divided into a basal,
mid, and apical segment and the apical, representing the 17th
segment. Wall motion score index is a semi-quantitative analysis
of regional systolic function. Each segment is analyzed individually
and scored on the basis of its motion and systolic thickening.
Ideally, the function of each segment should be conﬁrmed in
multiple views. This score is a 5-level score deﬁned as follows:
score 1 = normokinesis or hyperkinesis; score 2 = hypokinesis;
score 3 = akinesis; score 4 = dyskinesis; score 5 = aneurysm. Wall
motion score index is derived as a sum of all scores divided by the
number of segments visualized [15].
Perfusion myocardial scintigraphy
At 5–7 days after CICU admission, patients received an intravenous
injection of 27 mCi (1000 MBq) of technetium Tc-99m sestamibi.
Single-photon emission computed tomography (SPECT) was per-
formed within 6–8 h after the injection of the radioactive agent.
MIBG imaging
MIBG imaging was performed in all patients after CICU
admission, with a median of 14 days after presentation of the
symptoms, and at 12 months after the acute event. MIBG was
performed as previously reported [16]. Brieﬂy, the standard
protocol for 123I-MIBG cardiac imaging requires that drugs that
interfere with 123I-MIBG uptake should be withheld. Thyroid
uptake of unbound 123I was blocked with 500 mg of potassium
perchlorate given orally 30 min before 123I-MIBG injection.
Between 148 MBq and 370 MBq of 123I-MIBG were injected
intravenously at rest. Both planar and SPECT images were
acquired 15 min after injection (early) and 4 h after injection
(delayed). A dual head gamma camera (ECAM Siemens, Erlangen,
Germany) equipped with a low-energy, high-resolution collima-
tor was used. A 20% window was usually centered over the 159-
keV photo peak of 123I for imaging. Anterior planar images of the
chest were acquired using a 256  256 matrix. SPECT images were
acquired using a 64  64 matrix over 1808, from the right anterior
oblique position to the left posterior oblique position. Planar
imaging allowed for global assessment of cardiac innervation,
whereas SPECT allowed for regional evaluation. Quantitativeevaluations were performed with a standard protocol previously
described [16].
Laboratory analysis
Routine analysis
At admission, 14 days, and 12 months after the event, glycemia,
lipid proﬁle [total cholesterol (TC), triglycerides, high-density
lipoprotein cholesterol, and low-density lipoprotein cholesterol],
transaminases, creatine kinase (CK), and creatinine were evaluated.
Myocardial damage
Serum levels of troponin I, CK, and CK-MB were evaluated at
CICU admission.
Oxidative stress
At admission, 14 days, and 12 months after the event,
nitrotyrosine plasma concentration was assayed by enzyme-linked
immune sorbent assay (ELISA). Nitrotyrosine was determined as
the modiﬁed amino acid as a product of free-radical (O2)
interaction with nitric oxide (NO). The interaction of O2 with
NO is rapid and leads to inactivation of NO and production of the
potent oxidant peroxynitrite. Detection of nitrotyrosine is strongly
suggestive of increased generation of peroxynitrite [17].
Proinﬂammatory cytokines
Serum concentrations of tumor necrosis factor-a (TNF-a) were
determined in duplicate using a highly sensitive and quantitative
sandwich enzyme assay (Quantikine HS PharmPak, R&D, 395 Oys-
ter Point Blvd, Suite 321 South San Francisco, CA 94080, USA).
Plasma C-reactive protein (CRP) was determined using automated
turbidimetry.
Sympathetic tone
We evaluated the sympathetic activity at admission, 14 days,
and 12 months after the event, using laboratory analysis, by the
evaluation of catecholamine plasma levels. Circulating catechola-
mines may reﬂect the systemic sympathetic activity in affected
patients. Catecholamine plasma levels were measured by high-
performance liquid chromatography. Brain natriuretic peptide was
measured by enzyme immunoassay.
Study end point
The primary outcome was adrenergic cardiac innervation
improvement, determined in ALA group by quantitative MIBG at
12 months. The secondary outcome was inﬂammation markers
and oxidative stress reduction, and myocardial damage at
12 months after the initial event.
Statistical analysis
Data analysis
Data are shown as mean  standard deviation. A general linear
model (general form of ANOVA) was ﬁtted to the data, with treatment
group, sex, and age strata as the independent factors. When the
dependent variable was measured at 12 months, the baseline value was
also included as a covariate. Differences between groups were
considered signiﬁcant at p  0.05. For the signiﬁcance tests, we also
report the estimated adjusted mean difference between the groups, i.e.
antioxidant group-adjusted mean change – placebo group adjusted
mean change. Bonferroni post-hoc test was used for statistical analysis.
We report the analysis using data for participants who completed
the trial, i.e. had measurements performed at baseline and 12 months.
The analyses were performed using Sigma Plot 12 (Systat Software, Inc.
SigmaPlot for Windows, Chicago, IL, USA).
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The standard deviation of MIBG was assumed to be 0.0112,
based on previously published data on the magnitude of the
innervation deﬁcit observed in the distal myocardial segments of
TCM patients [18]. With 15 participants for each group, we
estimated 80% power to detect a change of 0.015 between the
mean MIBG of the placebo-treated and actively treated groups,
when testing the null hypothesis using a two-tailed two-sample t-
test at a 5% level of signiﬁcance. A 20% loss due to early
withdrawals and/or non-evaluable measurements was assumed
and, combined with the effect of stratiﬁcation on analysis, resulted
in the requirement to recruit 22 patients per treatment group.
Results
Clinical characteristics
We enrolled 48 participants who met the TCM inclusion criteria
(Fig. 1). The median age of TCM patients was 63.8  5.8 years. TCM
patients were all women and 47 of them were post-menopausal
(Table 1). Clinical characteristics for the entire cohort are summarized
in Table 1.Table 1
Patient characteristics.
ALA grou
Baseline 
Patients (n) 24 
Mean age (years) 63.7  6.5 
BMI (kg/m2) 27  1.62 
Waist-to-hip ratio 0.71  0.02 
Systolic blood pressure (mmHg) 122  9.9 
Diastolic blood pressure (mmHg) 81.3  15.4 
Heart rate (bpm) 97.5  7.86 
Blood glucose (mg/dl) 93.8  7.24 
Total cholesterol (mg/dl) 208.4  19.4 
Epinephrine (pg/ml) (IQR) 1013.5 (758–1240) 
Norepinephrine (pg/ml) (IQR) 2003.5 (1558–2665) 
Brain natriuretic peptide (pg/ml) (IQR) 995.5 (689–1240) 
C-reactive protein (mg/l) 3.8  0.8 
Tumor necrosis-a (pg/ml) 5.5  0.9 
Nitrotyrosine (mM) 0.5  0.1 
Smokers (% [n]) 17 (4) 
Previous disorder (% [n])
Hypertension 50 (12) 
Hyperlipidemia 44 (11) 
TroponinI (ng/ml) (IQR) 0.25 (0.15–0.60) 
CK (UI/l) 191.0 (95–304.5) 
CKMB (UI/l) 35.0 (26.5–43.0) 
Echocardiographic parameters
Admission LVEF, % 38  8 
Admission basal contraction, score 1.2  0.3 
Admission midventricle contraction, score 3.4  0.7 
Admission apical contraction, score 3.8  0.8 
LVEF, % at 14 days 45  10 
14 days basal contraction, score 1.1  0.1 
14 days mid-ventricular at contraction, score 1.8  0.6 
14 days apical segments contraction, score 2.1  0.7 
Discharge medication
Beta-blockers (% [n]) 96 (23) 
ACEi/ARB (% [n]) 66 (16) 
Aspirin (% [n]) 92 (22) 
Statin (% [n]) 83 (20) 
Representation of baseline characteristics of the patients assigned to either ALA or plac
range (IQR) according to their distribution.
ACEi, angiotensin-converting enzyme inhibitors; ALA, a-lipoic acid; ARB, angiotensin rece
type; LVEF, left ventricular ejection fraction. The * indicates a signiﬁcant p-value (p < 0.0
signiﬁcant p-value (p < 0.05) when comparing placebo group vs. ALA group. For troponin I,
ventricular and apical segments were only mildly hypokinetic, with echocardiographic sc
During echocardiographic examination at 14 days after admission, there were no s
randomization.Presentation and hospital outcome
All patients had severe chest pain, dyspnea, or both during
cardiovascular event and presented to the emergency department
a median of 2 h (interquartile range, one to ﬁve) after symptom
onset. All TCM patients had ST-segment elevation of at least 1 mm.
In TCM patients, troponin I peak levels were only mildly elevated,
with a median value of 0.25 ng/ml (interquartile range, 0.11–
0.58 ng/ml; normal value, <0.06 ng/ml). In TCM, CK and CK-MB
peak values were elevated with a median value of 191 UI/l
(interquartile range, 95–304 UI/l; normal value, 33–194 UI/l) and
192 UI/l (interquartile range, 95–304 UI/l; normal value, 33–
194 UI/l), 35 UI/l (interquartile range, 26.5–43 UI/l; normal value,
0–25 UI/l) and 37 UI/l (interquartile range, 28–44.5 UI/l; normal
value, 0–25 UI/l), respectively in the ALA group compared to
placebo. In TCM patients, the median left ventricular ejection
fraction (LVEF) on the initial echocardiogram (admission) was
38  9%. All TCM patients underwent emergency angiography on
admission. TCM patients had normal coronary arteries or mild
luminal irregularities, and no patient had angiographic epicardial
spasm evidence (Table 1). All TCM patients had a similar contractile
pattern, with preserved basal function, moderate-to-severe dysfunc-
tion in the mid-ventricle, and apical akinesis or dyskinesis (meanp Placebo group
12 months Baseline 12 months
22 24 21
63.2  6.1 63.9  5.2 63.1  5.9
26.9  1.8 27.6  2.2 27.3  1.85
0.7  0.02 0.72  0.03 0.71  0.03
121  8.8 123  11 122.5  10.4
78.5  10.7 82.2  8.27 79.7  5.7
78.9  10.2 98.3  5 78.16  10.69
96.6  10 94.8  9.12 96.7  13.34
201.6  20 206.3  15.9 199.7  19.09
370.5 (336–475)* 999 (885–1142) 366.5 (226–535)*
1047 (1009–1124)* 2012 (1778–2214) 1022 (1008–1137)*
135 (119–153)* 995 (669–1236) 146 (124–158)*
1.7  0.64* 3.6  0.8 2.7  0.7*z
2.1  0.95* 5.8  0.8 3.98  1*z
0.24  0.14* 0.5  0.08 0.46  0.12z
4 (1) 17 (4) 4 (1)
45 (10) 44 (11) 43 (9)
50 (11) 54 (13) 61 (13)
/ 0.25 (0.09–0.54) /
/ 192 (97–306) /
/ 37.0 (28–44.5) /
57.6  5.88 37  9 56  6
1  0.04 1.1  0.2 1.02  0.10
1.05  0.17 3.0  0.7 1.1  0.28
1.1  0.27 3.7  0.8 1.2  0.4
44  10
1.0  0.2
1.6  0.5
1.8  0.5
95 (21) 96 (23) 95 (20)
72 (16) 62 (15) 71 (15)
95 (21) 96 (23) 96 (23)
95 (21) 75 (18) 75 (18)
ebo treatment. Data are presented as mean  SD, n (%) or median and interquartile
ptor blockers; BMI, body mass index; CK, creatine kinase; CKMB, creatine kinase MB
5) in ALA and/or placebo group comparing follow-up vs. baseline. The z indicates a
 CK, and CKMB, peak values are reported. LVEF had improved to 45  10% and the mid-
ores of 1.1  0.1 at the base, 1.8  0.6 at the mid-ventricle, and 2.1  0.7 at the apex.
igniﬁcant differences in echocardiographic ﬁndings between the two groups of
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tively). By hospital day 14, LVEF had improved to 45  10% and the
mid-ventricular and apical segments were only mildly hypokinetic,
with echocardiographic scores of 1.1  0.1 at the base, 1.8  0.6 at the
mid-ventricle, and 2.1  0.7 at the apex (Table 1). For this reason, LVEF
did not signiﬁcantly increase (p > 0.05) under ALA regimen at
12 months compared to placebo group. Myocardial perfusion using
99mTc (n 53) was assessed at the sub-acute phase (at 5–7 days after the
event) in all patients. At rest, no signiﬁcant (>5% of the total myocardial
mass) impairment of myocardial perfusion was observed in TCM
patients at the sub-acute phase (data not shown). In all TCM patients,
the 123I-MIBG myocardial scintigraphy obtained 30 min after
administering radiotracer showed LV myocardial uptake reduction,
predominantly in the apical, anterior, and septo-apical segments and
lateral–apical, and inferior segments (Fig. 2). At admission, catecho-
lamines and B-type natriuretic peptide plasma levels were elevated in
all TCM patients (Table 1). By hospital day 14, in TCM patients
catecholamine plasma levels were one-third to one half of the peak
values: norepinephrine, 988 (668–1240) pg/ml; epinephrine, 589
(335–741) pg/ml. Plasma B-type natriuretic peptide levels declined
in all TCM patients: 225 (188–278) pg/ml. Moreover, at the onset of
TCM, CRP, TNF-a, and nitrotyrosine plasma levels were elevated
(Table 1). At day 14, they remained substantially elevated: CRP,
3.2  0.9 mg/l; TNF-a, 5.2  1.1 pg/ml; nitrotyrosine, 0.45  0.1 mM.
Intervention study
At discharge (a median of 14 days after presentation), TCM
patients were randomized to either ALA treatment or placeboFig. 2. Bar graphs representation of C-reactive protein (CRP), tumor necrosis factor a (T
patients) compared to placebo at follow-up. Data are expressed as mean and standar
compared to placebo. C-reactive protein was signiﬁcantly differently expressed at bas
p < 0.05) and in placebo group, respectively (3.6  0.8 mg/l vs. 2.7  0.7 mg/l, p < 0.05). T
follow-up in ALA group (5.5  0.9 pg/ml vs. 2.1  0.95 pg/ml, p < 0.05) and in placebo 
signiﬁcantly differently expressed at baseline and at 12 months follow-up in ALA group (0.5 
0.46  0.12 mM, p > 0.05).(24 participants per group) (Fig. 1). There were no signiﬁcant
differences in any of the demographic or other baseline
characteristics as well as full medical therapy of the study
population (Table 1). There were also no differences between
groups at baseline in systolic, and diastolic blood pressure,
catecholamine circulating levels, and resting heart rate
(Table 1). A total of 43 participants completed the 12-month
intervention, 21 in the placebo and 22 in the ALA group (Fig. 1). The
main reasons for study dropout are shown in Fig. 1. There was a
similar course in systolic and diastolic blood pressure, body mass
index, waste to hip ratio, and resting heart rate during the study in
both treatment groups (Table 1). At baseline, there were no
differences between the ALA and placebo groups in the CRP, TNF-a,
and nitrotyrosine levels as well as catecholamine levels (Table 1).
Compared with placebo, ALA supplementation resulted in
signiﬁcantly greater reductions in the CRP, TNF-a, and nitrotyr-
osine concentrations (Fig. 2). No differences between groups were
observed in the catecholamine and B-type natriuretic peptide
plasma levels and in the change between baseline and 12 months
(Table 1). LVEF, global, and regional echocardiographic contractile
patterns were similar in participants in both groups at baseline and
in the change between baseline and 12 months (Table 1). No
differences between groups were observed in the basal, mid-
ventricular, and apical echocardiographic segmental scores
(Table 1). The LVEF was increased slightly under the ALA regimen
at 12 months, as compared to placebo group (Table 1). This
difference did not reach statistical signiﬁcance (p = 0.59). At
baseline there were no differences between groups about global
or any regional MIBG myocardial scintigraphy (Fig. 3). The ALANF-alpha), and nitrotyrosine changes in patients who received a-lipoic acid (ALA
d deviation (SD) and the * indicates a signiﬁcant p-value (p < 0.05) in ALA group
eline and at 12-month follow-up in ALA group (3.8  0.8 mg/l vs. 1.7  0.64 mg/l,
umor necrosis-a was signiﬁcantly differently expressed at baseline and at 12-month
group, respectively (5.8  0.8 pg/ml vs. 3.98  1 pg/ml, p < 0.05). Nitrotyrosine was
 0.1 mM vs. 0.24  0.14 mM, p < 0.05), but not in the placebo group (0.5  0.08 mM vs.
Fig. 3. Bar graphs are the representation of data expressed as mean and standard deviation (SD). The * indicates a signiﬁcant p-value (p < 0.05) in a-lipoic acid (ALA) and/or
placebo group comparing follow-up vs. baseline. The z indicates a signiﬁcant p-value (p < 0.05) when comparing placebo group vs. ALA group. Data are presented as
mean + SD, data are distributed normally, and we have used ANOVA test for statistical comparisons. Upper part: representation of iodine 123 meta-iodobenzylguanidine
(123I MIBG) distribution in left ventricle at baseline and 12-month follow-up in patients who received ALA (left) compared to placebo (right).
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compared to placebo (p < 0.01) (Fig. 3). A signiﬁcant change from
baseline, a signiﬁcant MIBG defect size reduction was observed in
placebo-treated patients (p < 0.05) (Figs. 3 and 4). Analyses of the
regional MIBG also showed that the ALA treatment induced
considerably greater uptake increase predominantly in the apical,
anterior, and apical-septal segments and apical-lateral and inferior
segments (Figs. 3 and 5). After treatment, apical anterior and
apical-septal segments uptake changes were related to signiﬁcant
TNF-a and nitrotyrosine reductions (r = 0.38, p < 0.001, r = 0.29,
p < 0.01, respectively). There was a signiﬁcant difference between
ALA and placebo group after 12 months, because the 123-MIBG
defect reduction was greater in the ALA group compared to the
placebo group (p < 0.05) (Fig. 3). TCM recurred in 2 patients over a
12-month follow-up. Of note, the 2 patients with recurrent events
were assigned to placebo treatment. At the time of TCM recurrence,
there was no difference between the patients who did and did not
have recurrence in the aspirin, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers, beta-blockers, and statin
drugs being used. The small number of patients and recurrences
did not allow meaningful statistical analysis regarding factors
predicting the TCM recurrence as well as the ALA treatment effect
on the events.
Discussion
In the present study, for the ﬁrst time to our knowledge, we
demonstrated that 12-month ALA therapy improves sympathetic
heart function in patients with previous TCM experience. The
sympathetic activity dysfunction plays a key role in thepathophysiology of this reversible form of acute heart failure
[1–5], as conﬁrmed by our results about quantitative MIBG and
catecholamine and B-type natriuretic peptide plasma level
determination. Indeed, our data, according to the previous studies
[18], provided evidence of the apical myocardial 123I-MIBG uptake
impairment after 14 days from the acute event. Several mecha-
nisms were proposed to justify the myocardial 123I-MIBG uptake
reduction during acute phase. Distal denervation, following
myocyte permanent damage, has been observed in patients with
myocardial infarction [18]. In TCM patients, the normal coronary
perfusion and the progressive 123I-MIBG uptake improvement
both allow us to discard the hypothesis of myocardial sympathetic
denervation from myocardial infarction. Alternatively, the 123I-
MIBG uptake heterogeneity could be explained by the impairment
of the uptake-1 function, which is an altered failing heart ATP-
requiring system [19]. According to Owa et al. [20], we observed, in
TCM placebo-treated patients, the non-complete uptake normali-
zation of apical myocardial 123I-MIBG after 1-year follow-up. We
can hypothesize that a persisting normal b-adrenoceptor function
defected in the neurogenic stunned myocardium, in particular in
the apical region, may be responsible for TCM recurrence. At this
proposal, further larger studies including follow-up examinations
in patients with transient mid ventricular ballooning syndrome
could be interesting and particularly helpful. The mortality
analysis revealed that TCM patients are three times more likely
to die when compared to the general population [3]. After
discharge, the incidence of sudden death (2.6%) was not negligible,
and it merits further consideration. Currently, there are no data
available to recommend proper preventive strategies besides an
accurate patient follow-up, an aggressive cardiovascular risk factor
Fig. 4. Multiple slices from apex to base of short-axis, vertical long-axis and horizontal long-axis images, represented iodine 123 meta-iodobenzylguanidine (123I MIBG)
distribution in left ventricle at baseline and 12-month follow-up in a placebo patient. These images represent the assessment of myocardial 123I MIBG distribution in a
placebo patient with takotsubo cardiomyopathy at both subacute (baseline) and chronic phase (12 months). At baseline, 123I-mIBG uptake was severely reduced in the apex
and in the apical and mid segments of antero-septal left ventricle (LV) wall, whereas myocardial perfusion at rest was normal, showing only moderate apical contractile
dysfunction. 123I-mIBG scintigraphy was performed at 12-month follow-up after the acute symptomatology. At follow-up, images do not show an improvement of tracer
uptake in LV apical segments. In placebo-treated patient, at 12-month follow-up, there is a non-complete normalization of apical myocardial 123I-MIBG uptake.
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context, the adrenergic cardiac innervation improvement may be
beneﬁcial in TCM patients. Indeed, there are two major ﬁndings in
this study. First, we showed that ALA therapy is associated with a
slight but signiﬁcant left ventricle increased uptake as compared to
the placebo group. In more detail, regional MIBG analyses showed
that the ALA therapy induced a greater uptake increasing,
predominantly in the apical, anterior, and septo-apical segments
and lateral–apical and inferior segments. Second, we found that
after treatment, apical anterior and septo-apical segment uptake
changes were related to CRP, TNF-a, and nitrotyrosine blood level
reductions. Our data were comparable to the observed ALA
supplementation effects on diabetic cardiomyopathy [21]. Diabetic
cardiomyopathy is associated with cardiovascular autonomic
dysfunction, beginning at the apex of the ventricles, and
progressing toward the base [21]. The oxidative stress role in
diabetic cardiomyopathy pathophysiology is well known and an
antioxidant ALA treatment has been shown to completely prevent
heterogeneous MIBG distribution, decrease MIBG uptake, andincrease norepinephrine content in diabetic cardiomyopathy
[12,21]. Of note, the present study results indicate that ALA
therapy determined a signiﬁcant CRP, TNF-a, and nitrotyrosine
plasma level reductions in TCM-treated patients compared to the
placebo group. ALA acts by directly scavenging free radicals,
increasing the activity of catalase and superoxide dismutase, and
protecting peripheral nerves from lipid peroxidation [22,23]. In
addition, ALA improves the antioxidant defense system through
gene expression and inhibits nuclear factor kB [22,23]. In TCM
patients, ALA appears to act through a reduction of oxidative stress
and inﬂammation, as suggested by the strong evidence that
changes in the anterior-apical and septo-apical segments uptake,
after treatment, are related to TNF-a and nitrotyrosine reductions
(r = 0.38, p < 0.001, r = 0.29, p < 0.01, respectively). In line with our
evidence, the superoxide anion reduction, as well as the TNF-a
decrements, completely abolished the increased catecholamine
levels observed in heart failure [24]. Other heart failure markers,
such as the urinary albumin to creatinine ratio, the urinary 24 h
norepinephrine excretion, and high-sensitivity CRP levels, may
Fig. 5. Multiple slices from apex to base of short-axis, vertical long-axis and horizontal long-axis images represent iodine 123 meta-iodobenzylguanidine (123I MIBG)
distribution in left ventricle at baseline and 12-month follow-up in a patient with takotsubo cardiomyopathy who received a-lipoic acid (ALA). These images represent, at
baseline and at 12-month follow-up, the assessment of myocardial 123I MIBG distribution in ALA patient at both subacute (baseline) and chronic phase (12 months). In the
subacute phase, 123I-MIBG uptake was severely reduced in the apex and in the apical and mid segments of antero-septal left ventricle (LV) wall, whereas myocardial
perfusion at rest was normal, showing only moderate apical contractile dysfunction. 123I-MIBG scintigraphy was performed at 12-month follow-up after the acute
symptomatology. At follow-up images, there is a reduction of 123-MIBG defect, with greater increases of the tracer uptake predominantly in the apical, anterior, and apical-
septal LV segments.
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failure patients [25]. In fact, as authors have observed [25], the
right treatment may reduce these inﬂammatory markers and
partly mediate the reduction of albuminuria in heart failure. In our
study, all these controlled molecular effects have been observed,
described and correlated to the signiﬁcant left ventricle MIBG
uptake increase, predominantly in the apical, anterior, and septo-
apical segments and lateral–apical and inferior LV segments. ALA
therapy reducing oxidative stress and inﬂammation, and leading to
the improvement of the adrenergic cardiac innervations, may
control complex molecular pathways involved in LV coronary ﬂow
distribution in absence of coronary vessel obstructions. For these
reasons, ALA oral therapy may be the target treatment to restore a
defective LV segment vascularization in TCM-treated patients.
Study limitations
Study limitations include the limited power due to the
relatively low number of patients, the relatively short duration
of the study, and the limited assessment of changes in oxidative
stress and inﬂammatory markers. In conclusion, the novelty of this
study is that ALA treatment ameliorates the adrenergic cardiac
innervation dysfunction in TCM patients. Identifying the direct andor indirect ALA action mechanism at a molecular level may provide
an important novel insight for the improvement of therapeutic
strategies to target pathogenic transient cardiomyopathy mecha-
nisms such as takotsubo.
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